Viscardi, Giuseppe

Artificial Intelligence for Predictive Biomarker Discovery in Immuno-Oncology: A Systematic Review

Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S. E., Mazzeo, L., Provenzano, L., Kosta, S., et al. (2024) · Annals of Oncology

Cancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical Imaging

Cited by 340

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 110

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: A multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

Morgillo, F., Fasano, M., Della Corte, C. M., Sasso, F. C., Papaccio, F., Viscardi, G., Esposito, G., Di Liello, R., Normanno, N., Capuano, A., et al. (2017) · ESMO Open

Lung Cancer Treatments and MutationsMetabolism, Diabetes, and Cancer

Cited by 76

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients

Prelaj, A., Galli, E. G., Miskovic, V., Pesenti, M., Viscardi, G., Pedica, B., Mazzeo, L., Bottiglieri, A., Provenzano, L., Spagnoletti, A., et al. (2023) · Frontiers in Oncology

Cancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical Imaging

Cited by 39